CD28 and neoplasm: More recently, several groups have demonstrated that CTLA-4 and PD-1 inhibition works either directly or indirectly through suppression of CD28 costimulatory signaling8–10 and lack of sufficient T cell costimulation in the tumor microenvironment may be involved in primary or acquired resistance to CPI11–15.